Renalytix AI Stock Jumps After 10-Year US Government Contract For Kidney Disease Testing Services

by Vandana Singh, Benzinga Editor

April 22, 2021 7:58 AM | 1 min read |

Renalytix AI plc RNLX stock is rising on the heels of a 10-year contract from the United States Government to provide KidneyIntelX early-stage kidney disease bioprognostic testing services.
The contract, offered through the General Services Administration, covers laboratory testing services that can be provided through more than 140 U.S. government departments, agencies.
The contract is effective as of April 15 and has a five-year term with a five-year extension option.
Under the contract, KidneyIntelX pricing is set at $950 per reportable result.
Individual physicians operating within government-sponsored healthcare programs can now order KidneyIntelX testing for their patients with diabetic kidney disease.
Price Action: RNLX shares are up 21.7% at $30.7 in the premarket session on the last check Thursday.

Posted In: Biotech Government News Health Care Contracts Small Cap General Briefs kidney disease

Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.